TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03111524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Communication Resource
Description: The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Communication Resource
Description: The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Communication Resource
Description: The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Communication Resource
Description: The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Communication Resource
Description: The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention is administered in this group as these are control groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention is administered in this group as these are control groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention is administered in this group as these are control groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention is administered in this group as these are control groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention is administered in this group as these are control groups
Study: NCT02027025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC1103 low dose
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC1103 high dose
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPARC Placebo
Study: NCT01296802

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexfenfluramine
Description: oral, 40 mg to 60 mg, single application as a challenge
Study: NCT03717571

Intervention type: DIAGNOSTIC_TEST
Intervention: Glenohumeral translation assessment
Description: amount of glenohumeral translation under load

Intervention type: DIAGNOSTIC_TEST
Intervention: Glenohumeral translation assessment
Description: amount of glenohumeral translation under load
Study: NCT01012414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: 2 mcg oral paricalcitol daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04349839

Intervention type: DEVICE
Intervention: Acrodat software
Description: Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
Study: NCT03717571

Intervention type: DIAGNOSTIC_TEST
Intervention: Glenohumeral translation assessment
Description: amount of glenohumeral translation under load
Study: NCT00440440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel to be applied daily, starting does 5g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo gel apply daily
Study: NCT02513303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: A single dose of sirolimus delivered locally

Intervention type: PROCEDURE
Group type: OTHER
Intervention: AV Fistula Surgery
Description: AV Fistula Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV Fistula Surgery
Description: AV Fistula Surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Collagen Implant (SeCI)
Description: SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
Study: NCT04716062

Intervention type: PROCEDURE
Intervention: Open or Laparoscopic-assisted Colorectal surgery
Description: Colorectal surgery

Intervention type: PROCEDURE
Intervention: Open or Laparoscopic-assisted Colorectal surgery
Description: Colorectal surgery
Study: NCT04368364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine sulfate (ITM)
Description: Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine hydrochloride
Description: Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
Study: NCT01528345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dovitinib Placebo
Description: Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Study: NCT01821352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia Obesity Laser
Description: 10 independent 17 milliwatts 532 nm green diode lasers

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Emits light that has no therapeutic effect
Study: NCT03698903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Take a STAND 4 Health
Description: The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a STAND 4 Health
Description: The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
Study: NCT01580891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine HCl Cream 1%
Description: Naftifine HCl Cream 1% applied topically once a day for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® (Naftifine HCl) Cream 1%
Description: Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical cream
Description: Placebo topical cream applied topically once a day for 28 days.
Study: NCT01569672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator matched with subject
Description: Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Subjects are mailed informational/educational materials
Description: Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
Study: NCT04028726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back-squat exercise
Description: Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Back-squat exercise
Description: Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
Study: NCT02611947

Intervention type: RADIATION
Intervention: Low-dose chest CT scans
Description: Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm
Study: NCT03209479

Intervention type: DRUG
Intervention: Glatiramer acetate
Description: Copaxone subcutaneous injection syringe
Study: NCT03301636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously every 2 weeks starting on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally every 12 hours starting at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally every 12 hours starting at Day 1
Study: NCT01733277

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: All participants from both arms will be subjected to MRI

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: All participants from both arms will be subjected to MRI
Study: NCT00623532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body exercises
Study: NCT02910050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50mg once a day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
Study: NCT00623532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Tai-chi
Study: NCT02236000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Study: NCT02624791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests
Study: NCT04559763

Intervention type: DEVICE
Intervention: Non-Invasive Controlled Hypoxia
Description: Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.

Intervention type: OTHER
Intervention: Introduction of Motion conditions: tapping or rubbing
Description: Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
Study: NCT02935660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Laser tattoo removal treatment
Study: NCT02943239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Description: REGN1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Description: REGN1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Description: REGN1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Description: REGN1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Description: REGN1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00400127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silesian suspension belt
Study: NCT00935727

Intervention type: OTHER
Group type: OTHER
Intervention: Elastographic imaging
Description: ultrasound imaging using a specialized computer that processes the data for tissue hardness

Intervention type: OTHER
Group type: OTHER
Intervention: Elastographic imaging
Description: ultrasound imaging using a specialized computer that processes the data for tissue hardness

Intervention type: OTHER
Group type: OTHER
Intervention: Elastographic imaging
Description: ultrasound imaging using a specialized computer that processes the data for tissue hardness
Study: NCT04305717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDS-guided strategy
Description: A discharge scheme based on specific target value given by the device
Study: NCT02341729

Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor
Description: crushed tablets and non-crushed tablets
Study: NCT01577459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA with PSE
Description: TR-701 FA Oral 200 mg oral with PSE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TR-701 FA Placebo with PSE
Description: TR-701 FA Placebo Oral 200 mg with PSE
Study: NCT02707549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Study: NCT03736655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interposition supraciliary implant
Description: Surgical placement of an interposition supraciliary implant in the supraciliary space
Study: NCT00182559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.